患者来源的器官小球在基础科学和向个体化医学以及革命性药物研发方向的转化应用中正日益受到青睐。然而，对于肿瘤小球而言，仍存在器官小球生长率低、肿瘤细胞纯度低的挑战，即构建的小球中肿瘤表型的重现。本文报道了一种微流控液滴封装的方法，为肿瘤细胞的生长和组织结构提供结构指导，使之发展为具有高纯度和高建模成功率的肿瘤小球，与传统的非工程小球建模方法相比，即非工程小球。通过组织学检查，对病人来源的样本进行了建模效力和小球质量的检验，涵盖了食道癌、肺癌和结直肠癌组织，这些都证明在液滴工程小球中有显著的意义。© 2023 UICC。

Patient-derived organoids are gaining incremental popularity in both basic sciences and translational applications toward precision medicine and revolutionized drug discovery. However, for tumor organoids, challenges remain in low rates of organoid growth and tumor cell purity, that is, recapitulation of tumor phenotypes in constructed organoids. Here, we report a method of microfluidic droplet encapsulation that provides structural guidance for tumor cell growth and organization, where they develop into tumor organoids with high purity and high rates of modeling success, as compared to the classical organoid modeling method, that is, non-engineered organoids. The modeling efficacy and organoid quality are examined in patient-derived samples, covering esophagus, lung and colorectal cancer tissues, all proving significance in droplet-engineered organoids, as demonstrated by histological examinations.© 2023 UICC.